|
시장보고서
상품코드
2016048
분자 세포 유전학 시장 보고서 : 제품 유형, 기술, 용도, 최종사용자, 지역별(2026-2034년)Molecular Cytogenetics Market Report by Product Type, Technology (Comparative Genomic Hybridization, Fluorescence in SITU Hybridization, Immunohistochemistry, Karyotyping, and Others), Application, End User, and Region 2026-2034 |
||||||
세계의 분자 세포 유전학 시장 규모는 2025년에 32억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 66억 달러에 달하며, 2026-2034년에 CAGR 8.28%로 성장할 것으로 예측하고 있습니다.
분자세포유전학은 유전자의 돌연변이 및 질병을 조사하기 위한 데옥시리보핵산(DNA)의 메커니즘에 대한 생의학적인 연구를 말합니다. 특히 의학 및 암 관련 유전학에서 염색체와 그 핵의 구조적, 기능적 조직, 게놈 돌연변이, 발현, 진화 및 이상에 대해 연구합니다. DNA 증폭, DNA 추출, 유전자 스크리닝, 가상 핵형 분석 및 형광 in situ hybridization(FISH) 등의 기술은 DNA 프로브를 사용하여 게놈 또는 그 표적 영역을 시각화 및 표지함으로써 분자 세포 유전학에서 일반적으로 사용되고 있습니다. 이러한 기술은 다양한 악성 종양 및 혈액 악성 종양의 진단 및 치료에 매우 유용합니다.
암 및 기타 유전성 질환의 유병률 증가와 고령 인구의 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 분자세포유전학은 주로 질병의 특성에 대한 예측 모델과 효과적인 치료 전략 개발에 활용되고 있습니다. 또한 암 치료에서 표적치료제의 보급도 시장 성장을 촉진하고 있습니다. FISH와 비교유전체하이브리데이션(CGH)은 암의 진행 단계를 분석하고 환자에게 맞춤형 치료를 제공하기 위한 약물유전체학 바이오마커 연구에도 활용되고 있습니다. 또한 개선된 소모품, 시약, 소프트웨어, 키트 개발 등 다양한 기술 발전도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 이러한 발전은 재현성이 높고 정확하고 신뢰할 수 있는 임상병리 검사 결과를 생성하는 데 기여하고 있습니다. 헬스케어 인프라의 대폭적인 개선, 생물 의학 분야의 광범위한 연구개발(R&D) 활동과 같은 다른 요인들도 시장 확대를 견인할 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 분자 세포 유전학 시장
제6장 시장 내역 : 제품 유형별
제7장 시장 내역 : 기술별
제8장 시장 내역 : 용도별
제9장 시장 내역 : 최종사용자별
제10장 시장 내역 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KSA 26.05.06The global molecular cytogenetics market size reached USD 3.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 6.6 Billion by 2034, exhibiting a growth rate (CAGR) of 8.28% during 2026-2034.
Molecular cytogenetics refers to the biomedical research of deoxyribonucleic acid (DNA) mechanisms to investigate genetic mutations and disorders. It studies the structural and functional organization of the chromosomes and their nucleus, genomic variations, expression, evolution and abnormalities, especially in medicinal and cancer-related genetics. Techniques such as DNA amplification, DNA isolation, gene screens, virtual karyotyping and fluorescence in situ hybridization (FISH) are commonly used for molecular cytogenetics by using DNA probes to visualize and label the genome or its targeted regions. These techniques are highly beneficial in the diagnosis and treatment of various malignant tumors and hematological malignancies.
The increasing prevalence of cancer and other genetic disorders, along with the rising geriatric population, is one of the key factors driving the growth of the market. Molecular cytogenetics is primarily being used for developing predictive models of disease traits and effective treatment strategies. Furthermore, the widespread adoption of targeted therapies for cancer treatment is also augmenting the market growth. FISH and Comparative Genomic Hybridization (CGH) are also used for pharmacogenomic biomarker studies to analyze cancer progression stages and provide personalized treatment to the patient. Additionally, various technological advancements, such as the development of improved consumables, reagents, software and kits, are acting as other growth-inducing factors. These advancements aid in generating duplicatable, accurate and reliable clinical-pathological test results. Other factors, including significant improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities in the field of biomedical sciences, are anticipated to drive the market further.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global molecular cytogenetics market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on product type, technology, application and end user.
Breakup by Product Type:
- Instruments
- Consumables
- Software and Services
- Others
Breakup by Technology:
- Comparative Genomic Hybridization
- Fluorescence in SITU Hybridization (FISH)
- Immunohistochemistry
- Karyotyping
- Others
Breakup by Application:
- Genetic Disorders
- Oncology
- Personalized Medicine
- Others
Breakup by End User:
- Clinical and Research Laboratories
- Hospitals and Pathology Laboratories
- Pharmaceutical and Biotechnology Companies
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Applied Spectral Imaging Inc., Biological Industries, Bio-RAD Laboratories Inc., BioView Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Illumina Inc., Oxford Gene Technology, Perkinelmer Inc. and Quest Diagnostics Incorporated.
Key Questions Answered in This Report
1. What was the size of the global molecular cytogenetics market in 2025?
2. What is the expected growth rate of the global molecular cytogenetics market during 2026-2034?
3. What has been the impact of COVID-19 on the global molecular cytogenetics market?
4. What are the key factors driving the global molecular cytogenetics market?
5. What is the breakup of the global molecular cytogenetics market based on the product type?
6. What is the breakup of the global molecular cytogenetics market based on the technology?
7. What is the breakup of the global molecular cytogenetics market based on application?
8. What is the breakup of the global molecular cytogenetics market based on the end user?
9. What are the key regions in the global molecular cytogenetics market?
10. Who are the key players/companies in the global molecular cytogenetics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Molecular Cytogenetics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Instruments
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Consumables
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Software and Services
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Technology
- 7.1 Comparative Genomic Hybridization
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Fluorescence in SITU Hybridization (FISH)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Immunohistochemistry
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Karyotyping
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Application
- 8.1 Genetic Disorders
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Oncology
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Personalized Medicine
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by End User
- 9.1 Clinical and Research Laboratories
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Hospitals and Pathology Laboratories
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Pharmaceutical and Biotechnology Companies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Agilent Technologies Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Applied Spectral Imaging Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.4 Biological Industries
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Bio-RAD Laboratories Inc.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 BioView Inc.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.7 Danaher Corporation
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 F. Hoffmann-La Roche AG
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 SWOT Analysis
- 15.3.9 Illumina Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Oxford Gene Technology
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.11 Perkinelmer Inc.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Quest Diagnostics Incorporated
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.1 Abbott Laboratories
